Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.

Abstract

Data on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccinations in hepatocellular carcinoma (HCC) patients are limited. In this multicenter prospective study, HCC patients received two doses of inactivated whole-virion COVID-19 vaccines. The safety and neutralizing antibody were monitored. Totally, 74 patients were enrolled from 10 centers in China, and 37 (50.0%), 25 (33.8%), and 12 (16.2%) received the CoronaVac, BBIBP-CorV, and WIBP-CorV, respectively. The vaccines were well tolerated, where pain at the injection site (6.8% [5/74]) and anorexia (2.7% [2/74]) were the most frequent local and systemic adverse events. The median level of neutralizing antibody was 13.5 (interquartile range [IQR]: 6.9-23.2) AU/ml at 45 (IQR: 19-72) days after the second dose of vaccinations, and 60.8% (45/74) of patients had positive neutralizing antibody. Additionally, lower γ-glutamyl transpeptidase level was related to positive neutralizing antibody (odds ratio = 1.022 [1.003-1.049], p = 0.049). In conclusion, this study found that inactivated COVID-19 vaccinations are safe and the immunogenicity is acceptable or hyporesponsive in patients with HCC. Given that the potential benefits may outweigh the risks and the continuing emergences of novel severe acute respiratory syndrome coronavirus 2 variants, we suggest HCC patients to be vaccinated against COVID-19. Future validation studies are warranted.

• Authors: Xiaolong Qi, Jitao Wang, Qiran Zhang, Jingwen Ai, Chuan Liu, Qianqian Li, Ye Gu, Jiaojian Lv, Yifei Huang, Yanna Liu, Dan Xu, Shubo Chen, Dengxiang Liu, Jinlong Li, Huiling Xiang, Jing Liang, Li Bian, Zhen Zhang, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiufang Du, Aifang Hou, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Shengqiang Zou, Hailei Ji, Guohong Ge, Qing-Lei Zeng, Wenhong Zhang
• Journal: Journal of medical virology (J Med Virol) Vol. 94 Issue 11 Pg. 5553-5559 (11 2022) ISSN: 1096-9071 [Electronic] United States
• PMID: 35811309 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• COVID-19 Vaccines

Topics

• Antibodies, Neutralizing
• Antibodies, Viral
• COVID-19 (prevention & control)
• COVID-19 Vaccines (adverse effects)
• Carcinoma, Hepatocellular
• Humans
• Immunogenicity, Vaccine
• Liver Neoplasms
• Prospective Studies
• SARS-CoV-2
• Vaccination (adverse effects)